The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries
View ORCID ProfileAllison Portnoy, View ORCID ProfileJean-Louis Arcand, View ORCID ProfileRebecca A. Clark, View ORCID ProfileChathika K. Weerasuriya, View ORCID ProfileChristinah Mukandavire, View ORCID ProfileRoel Bakker, View ORCID ProfileEdith Patouillard, View ORCID ProfileNebiat Gebreselassie, View ORCID ProfileMatteo Zignol, View ORCID ProfileMark Jit, View ORCID ProfileRichard G. White, View ORCID ProfileNicolas A. Menzies
doi: https://doi.org/10.1101/2022.11.23.22282690
Allison Portnoy
1Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Jean-Louis Arcand
2Department of International Economics, The Graduate Institute of International and Development Studies, Geneva, Switzerland
3Fondation pour les études et recherches sur le développement international (FERDI), Clermont-Ferrand, France
Rebecca A. Clark
4TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Chathika K. Weerasuriya
4TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Christinah Mukandavire
4TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Roel Bakker
4TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
7KNCV Tuberculosis Foundation, The Hague, Netherlands
Edith Patouillard
8Department of Health Systems Governance and Financing, World Health Organization, Geneva, Switzerland
Nebiat Gebreselassie
9Global TB Programme, World Health Organization, Geneva, Switzerland
Matteo Zignol
9Global TB Programme, World Health Organization, Geneva, Switzerland
Mark Jit
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
10School of Public Health, University of Hong Kong, Hong Kong SAR, China
Richard G. White
4TB Modelling Group, London School of Hygiene and Tropical Medicine, London, UK
5Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Nicolas A. Menzies
1Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
11Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Article usage
Posted November 28, 2022.
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries
Allison Portnoy, Jean-Louis Arcand, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies
medRxiv 2022.11.23.22282690; doi: https://doi.org/10.1101/2022.11.23.22282690
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries
Allison Portnoy, Jean-Louis Arcand, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies
medRxiv 2022.11.23.22282690; doi: https://doi.org/10.1101/2022.11.23.22282690
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)